Taken together, the presence of a GNAS mutation—whether in cyst fluid, tissue, or cfDNA—provides a highly specific molecular signature for IPMN and a practical discriminator from MCN and other non-mucinous entities. Here, GNAS is linked to pancreatic intraductal papillary-mucinous neoplasm.